What other research is promising, and where do you expect myeloma research to be in 5 years?
Chapter 1In this segment, Dr Lesokhin discusses new and emerging classes of drugs likely to transform treatment for patients with myeloma.
Chapter 2
PD-1 inhibition is noted as very promising for myeloma, though clinical trials haven’t shown a promising ORR. Why do you think this is?
In this segment, Dr Lesokhin discusses the potential of checkpoint inhibition for multiple myeloma.
Chapter 3
Can anything be done to mitigate the toxicity of PD-1/PD-L1 inhibition in myeloma?
In this segment, Dr Lesokhin discusses the management of toxicity related to PD-1 blockade in myeloma, including the possibility of re-challenge.
Chapter 4
What potential does CAR-T cell therapy have in myeloma?
In this segment, Dr Lesokhin discusses how CAR-T cell therapy may be used in patients with multiple myeloma.
